Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer

Li Yang, Joseph M. Amann, Takefumi Kikuchi, Rut Porta, Marta Guix, Adriana Gonzalez, Kyung Ho Park, David D Billheimer, Carlos L. Arteaga, Hsin Hsiung Tai, Raymond DuBois, David P. Carbone, David H. Johnson

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Evidence indicates that the induction of cyclooxygenase-2 (COX-2) and high prostaglandin E2 (PGE2) levels contribute to the pathogenesis of non-small-cell lung cancer (NSCLC). In addition to overproduction by COX-2, PGE2 concentrations also depend upon the levels of the PGE2 catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). We find a dramatic down-regulation of PGDH protein in NSCLC cell lines and in resected human tumors when compared with matched normal lung. Affymetrix array analysis of 10 normal lung tissue samples and 49 resected lung tumors revealed a much lower expression of PGDH transcripts in all NSCLC histologic groups. In addition, treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib increased the expression of 15-PGDH in a subset of NSCLC cell lines. This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results. We show by quantitative reverse transcription-PCR that the transcript levels of ZEB1 and Slug transcriptional repressors are dramatically reduced in a responsive cell line upon EGFR and MEK/ERK inhibition. In addition, the Slug protein, but not ZEB1, binds to the PGDH promoter and represses transcription. As these repressors function by recruiting histone deacetylases to promoters, it is likely that PGDH is repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased PGE 2 activity in tumors. This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI.

Original languageEnglish (US)
Pages (from-to)5587-5593
Number of pages7
JournalCancer Research
Volume67
Issue number12
DOIs
StatePublished - Jun 15 2007
Externally publishedYes

Fingerprint

15-hydroxyprostaglandin dehydrogenase
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mitogen-Activated Protein Kinase Kinases
Dinoprostone
Gastropoda
Extracellular Signal-Regulated MAP Kinases
Cyclooxygenase 2
Cell Line
Protein-Tyrosine Kinases
Lung
Neoplasms
Histone Deacetylases
Prostaglandins E
Epigenomics
Histones
Reverse Transcription
Proteins
Down-Regulation
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. / Yang, Li; Amann, Joseph M.; Kikuchi, Takefumi; Porta, Rut; Guix, Marta; Gonzalez, Adriana; Park, Kyung Ho; Billheimer, David D; Arteaga, Carlos L.; Tai, Hsin Hsiung; DuBois, Raymond; Carbone, David P.; Johnson, David H.

In: Cancer Research, Vol. 67, No. 12, 15.06.2007, p. 5587-5593.

Research output: Contribution to journalArticle

Yang, L, Amann, JM, Kikuchi, T, Porta, R, Guix, M, Gonzalez, A, Park, KH, Billheimer, DD, Arteaga, CL, Tai, HH, DuBois, R, Carbone, DP & Johnson, DH 2007, 'Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer', Cancer Research, vol. 67, no. 12, pp. 5587-5593. https://doi.org/10.1158/0008-5472.CAN-06-2287
Yang, Li ; Amann, Joseph M. ; Kikuchi, Takefumi ; Porta, Rut ; Guix, Marta ; Gonzalez, Adriana ; Park, Kyung Ho ; Billheimer, David D ; Arteaga, Carlos L. ; Tai, Hsin Hsiung ; DuBois, Raymond ; Carbone, David P. ; Johnson, David H. / Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. In: Cancer Research. 2007 ; Vol. 67, No. 12. pp. 5587-5593.
@article{16a18efc43604e72a774b0c47c0c6a55,
title = "Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer",
abstract = "Evidence indicates that the induction of cyclooxygenase-2 (COX-2) and high prostaglandin E2 (PGE2) levels contribute to the pathogenesis of non-small-cell lung cancer (NSCLC). In addition to overproduction by COX-2, PGE2 concentrations also depend upon the levels of the PGE2 catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). We find a dramatic down-regulation of PGDH protein in NSCLC cell lines and in resected human tumors when compared with matched normal lung. Affymetrix array analysis of 10 normal lung tissue samples and 49 resected lung tumors revealed a much lower expression of PGDH transcripts in all NSCLC histologic groups. In addition, treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib increased the expression of 15-PGDH in a subset of NSCLC cell lines. This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results. We show by quantitative reverse transcription-PCR that the transcript levels of ZEB1 and Slug transcriptional repressors are dramatically reduced in a responsive cell line upon EGFR and MEK/ERK inhibition. In addition, the Slug protein, but not ZEB1, binds to the PGDH promoter and represses transcription. As these repressors function by recruiting histone deacetylases to promoters, it is likely that PGDH is repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased PGE 2 activity in tumors. This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI.",
author = "Li Yang and Amann, {Joseph M.} and Takefumi Kikuchi and Rut Porta and Marta Guix and Adriana Gonzalez and Park, {Kyung Ho} and Billheimer, {David D} and Arteaga, {Carlos L.} and Tai, {Hsin Hsiung} and Raymond DuBois and Carbone, {David P.} and Johnson, {David H.}",
year = "2007",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-06-2287",
language = "English (US)",
volume = "67",
pages = "5587--5593",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer

AU - Yang, Li

AU - Amann, Joseph M.

AU - Kikuchi, Takefumi

AU - Porta, Rut

AU - Guix, Marta

AU - Gonzalez, Adriana

AU - Park, Kyung Ho

AU - Billheimer, David D

AU - Arteaga, Carlos L.

AU - Tai, Hsin Hsiung

AU - DuBois, Raymond

AU - Carbone, David P.

AU - Johnson, David H.

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Evidence indicates that the induction of cyclooxygenase-2 (COX-2) and high prostaglandin E2 (PGE2) levels contribute to the pathogenesis of non-small-cell lung cancer (NSCLC). In addition to overproduction by COX-2, PGE2 concentrations also depend upon the levels of the PGE2 catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). We find a dramatic down-regulation of PGDH protein in NSCLC cell lines and in resected human tumors when compared with matched normal lung. Affymetrix array analysis of 10 normal lung tissue samples and 49 resected lung tumors revealed a much lower expression of PGDH transcripts in all NSCLC histologic groups. In addition, treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib increased the expression of 15-PGDH in a subset of NSCLC cell lines. This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results. We show by quantitative reverse transcription-PCR that the transcript levels of ZEB1 and Slug transcriptional repressors are dramatically reduced in a responsive cell line upon EGFR and MEK/ERK inhibition. In addition, the Slug protein, but not ZEB1, binds to the PGDH promoter and represses transcription. As these repressors function by recruiting histone deacetylases to promoters, it is likely that PGDH is repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased PGE 2 activity in tumors. This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI.

AB - Evidence indicates that the induction of cyclooxygenase-2 (COX-2) and high prostaglandin E2 (PGE2) levels contribute to the pathogenesis of non-small-cell lung cancer (NSCLC). In addition to overproduction by COX-2, PGE2 concentrations also depend upon the levels of the PGE2 catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). We find a dramatic down-regulation of PGDH protein in NSCLC cell lines and in resected human tumors when compared with matched normal lung. Affymetrix array analysis of 10 normal lung tissue samples and 49 resected lung tumors revealed a much lower expression of PGDH transcripts in all NSCLC histologic groups. In addition, treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib increased the expression of 15-PGDH in a subset of NSCLC cell lines. This effect may be due in part to an inhibition of the extracellular signal-regulated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor U0126 mimics the erlotinib results. We show by quantitative reverse transcription-PCR that the transcript levels of ZEB1 and Slug transcriptional repressors are dramatically reduced in a responsive cell line upon EGFR and MEK/ERK inhibition. In addition, the Slug protein, but not ZEB1, binds to the PGDH promoter and represses transcription. As these repressors function by recruiting histone deacetylases to promoters, it is likely that PGDH is repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased PGE 2 activity in tumors. This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI.

UR - http://www.scopus.com/inward/record.url?scp=34250815766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250815766&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2287

DO - 10.1158/0008-5472.CAN-06-2287

M3 - Article

C2 - 17575121

AN - SCOPUS:34250815766

VL - 67

SP - 5587

EP - 5593

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -